Pacira | PCRX - Interest Expense On Debt


Pacira reported $112.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Astellas Pharma JPY 3.91B 320M Mar/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
J&J USD 43M 25M Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novo Nordisk DKK 1.5B 28M Jun/2026
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 112.4M 108.78M Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
Xeris Pharmaceuticals USD 6.95M 63K Jun/2026
Zoetis USD 62M 1000K Sep/2026